vs

Side-by-side financial comparison of Edwards Lifesciences (EW) and Fabrinet (FN). Click either name above to swap in a different company.

Edwards Lifesciences is the larger business by last-quarter revenue ($1.6B vs $1.1B, roughly 1.5× Fabrinet). Edwards Lifesciences runs the higher net margin — 23.1% vs 9.9%, a 13.2% gap on every dollar of revenue. On growth, Fabrinet posted the faster year-over-year revenue change (35.9% vs 16.7%). Over the past eight quarters, Fabrinet's revenue compounded faster (24.4% CAGR vs 9.7%).

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.

Below is a list of companies having stocks that are included in the S&P MidCap 400 stock market index. The index, maintained by S&P Dow Jones Indices, comprises the common stocks of 400 mid-cap, mostly American, companies. Although called the S&P 400, the index sometimes contains more than 400 stocks when it includes two or more share classes of stock from one of its component companies.

EW vs FN — Head-to-Head

Bigger by revenue
EW
EW
1.5× larger
EW
$1.6B
$1.1B
FN
Growing faster (revenue YoY)
FN
FN
+19.2% gap
FN
35.9%
16.7%
EW
Higher net margin
EW
EW
13.2% more per $
EW
23.1%
9.9%
FN
Faster 2-yr revenue CAGR
FN
FN
Annualised
FN
24.4%
9.7%
EW

Income Statement — Q1 FY2026 vs Q2 FY2026

Metric
EW
EW
FN
FN
Revenue
$1.6B
$1.1B
Net Profit
$380.7M
$112.6M
Gross Margin
78.0%
12.2%
Operating Margin
1.8%
10.1%
Net Margin
23.1%
9.9%
Revenue YoY
16.7%
35.9%
Net Profit YoY
6.8%
30.0%
EPS (diluted)
$0.66
$3.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EW
EW
FN
FN
Q1 26
$1.6B
Q4 25
$1.6B
$1.1B
Q3 25
$1.6B
$978.1M
Q2 25
$1.5B
$909.7M
Q1 25
$1.4B
$871.8M
Q4 24
$1.4B
$833.6M
Q3 24
$1.4B
$804.2M
Q2 24
$1.4B
$753.3M
Net Profit
EW
EW
FN
FN
Q1 26
$380.7M
Q4 25
$91.2M
$112.6M
Q3 25
$291.1M
$95.9M
Q2 25
$333.2M
$87.2M
Q1 25
$358.0M
$81.3M
Q4 24
$385.6M
$86.6M
Q3 24
$3.1B
$77.4M
Q2 24
$366.3M
$81.1M
Gross Margin
EW
EW
FN
FN
Q1 26
78.0%
Q4 25
78.1%
12.2%
Q3 25
77.8%
11.9%
Q2 25
77.5%
12.2%
Q1 25
78.7%
11.7%
Q4 24
78.9%
12.1%
Q3 24
80.6%
12.3%
Q2 24
79.9%
12.3%
Operating Margin
EW
EW
FN
FN
Q1 26
1.8%
Q4 25
9.6%
10.1%
Q3 25
19.8%
9.6%
Q2 25
26.8%
9.8%
Q1 25
27.9%
9.0%
Q4 24
22.6%
9.5%
Q3 24
25.9%
9.6%
Q2 24
26.8%
9.7%
Net Margin
EW
EW
FN
FN
Q1 26
23.1%
Q4 25
5.8%
9.9%
Q3 25
18.7%
9.8%
Q2 25
21.7%
9.6%
Q1 25
25.3%
9.3%
Q4 24
27.8%
10.4%
Q3 24
226.7%
9.6%
Q2 24
26.7%
10.8%
EPS (diluted)
EW
EW
FN
FN
Q1 26
$0.66
Q4 25
$0.16
$3.11
Q3 25
$0.50
$2.66
Q2 25
$0.56
$2.41
Q1 25
$0.61
$2.25
Q4 24
$0.65
$2.38
Q3 24
$5.13
$2.13
Q2 24
$0.61
$2.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EW
EW
FN
FN
Cash + ST InvestmentsLiquidity on hand
$960.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.2B
Total Assets
$3.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EW
EW
FN
FN
Q1 26
Q4 25
$4.2B
$960.8M
Q3 25
$3.8B
$968.8M
Q2 25
$4.1B
$934.2M
Q1 25
$3.9B
$950.7M
Q4 24
$4.0B
$934.6M
Q3 24
$4.4B
$908.9M
Q2 24
$2.0B
$858.6M
Stockholders' Equity
EW
EW
FN
FN
Q1 26
Q4 25
$10.3B
$2.2B
Q3 25
$10.2B
$2.1B
Q2 25
$10.5B
$2.0B
Q1 25
$10.1B
$1.9B
Q4 24
$10.0B
$1.8B
Q3 24
$9.5B
$1.8B
Q2 24
$7.4B
$1.7B
Total Assets
EW
EW
FN
FN
Q1 26
Q4 25
$13.7B
$3.3B
Q3 25
$13.3B
$3.0B
Q2 25
$13.5B
$2.8B
Q1 25
$13.0B
$2.6B
Q4 24
$13.1B
$2.5B
Q3 24
$13.0B
$2.4B
Q2 24
$10.1B
$2.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EW
EW
FN
FN
Operating Cash FlowLast quarter
$46.3M
Free Cash FlowOCF − Capex
$-5.3M
FCF MarginFCF / Revenue
-0.5%
Capex IntensityCapex / Revenue
4.6%
Cash ConversionOCF / Net Profit
0.41×
TTM Free Cash FlowTrailing 4 quarters
$102.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EW
EW
FN
FN
Q1 26
Q4 25
$450.9M
$46.3M
Q3 25
$573.7M
$102.6M
Q2 25
$290.2M
$55.1M
Q1 25
$280.4M
$74.2M
Q4 24
$-127.5M
$115.9M
Q3 24
$351.8M
$83.2M
Q2 24
$371.5M
$83.1M
Free Cash Flow
EW
EW
FN
FN
Q1 26
Q4 25
$353.5M
$-5.3M
Q3 25
$516.2M
$57.3M
Q2 25
$240.9M
$4.7M
Q1 25
$224.4M
$45.7M
Q4 24
$-177.3M
$94.0M
Q3 24
$299.9M
$62.9M
Q2 24
$286.1M
$70.4M
FCF Margin
EW
EW
FN
FN
Q1 26
Q4 25
22.5%
-0.5%
Q3 25
33.2%
5.9%
Q2 25
15.7%
0.5%
Q1 25
15.9%
5.2%
Q4 24
-12.8%
11.3%
Q3 24
22.1%
7.8%
Q2 24
20.9%
9.3%
Capex Intensity
EW
EW
FN
FN
Q1 26
Q4 25
6.2%
4.6%
Q3 25
3.7%
4.6%
Q2 25
3.2%
5.5%
Q1 25
4.0%
3.3%
Q4 24
3.6%
2.6%
Q3 24
3.8%
2.5%
Q2 24
6.2%
1.7%
Cash Conversion
EW
EW
FN
FN
Q1 26
Q4 25
4.94×
0.41×
Q3 25
1.97×
1.07×
Q2 25
0.87×
0.63×
Q1 25
0.78×
0.91×
Q4 24
-0.33×
1.34×
Q3 24
0.11×
1.07×
Q2 24
1.01×
1.02×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EW
EW

Segment breakdown not available.

FN
FN

Optical Communications$832.6M73%
Non Optical Communications$300.3M27%

Related Comparisons